Asparagine synthetase is partially localized to the plasma membrane and upregulated by L-asparaginase in U937 cells

Abstract

This study investigated the intracellular localization of asparagine synthetase (ASNS) in the relation with chemoresistance in leukemia. pIRES-GFP-ASNS-Flag/Neo expression vector was transiently tansfected into SK-N-MC cells and 297T cells respectively. Immunofluorescence and Western blot analysis were performed for cellular localization of ASNS respectively. U937 cells were treated with L-asparaginase for 48 h and examined for endogenous ASNS expression on plasma membrane by immunofluorescence staining. Immunofluorescence staining showed that the transiently expressed ASNS was partly localized on transfected-SK-N-MC cell surface. Moreover, Western blotting exhibited that ASNS expressed both in cytosol and on plasma membrane of transfected-293T cells. Immunofluorescence staining with anti-ASNS-specific monoclonal antibody revealed that endogenous ASNS was localized on the plasma membrane of U937 cells, except for its distribution in the cytosol. In addition, ASNS exhibited a higher expression on plasma membrane after treatment with L-asparaginase as compared with the untreated cells. It was concluded that the subcellular translocation of ASNS may play an important role in L-asparaginase resistance in leukemia cells.

Keywords

asparagine synthetase / L-asparaginase / acute myeloid leukemia / drug resistance / plasma membrane

References

[1] PuiC.H., EvansW.E.. Treatment of acute lymphoblastic leukemia. N Engl J Med, 2006, 354(2): 166-178

[2] ZwaanC.M., KaspersG.J., PietersR., et al.. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood, 2000, 96(8): 2879-2886

[3] KaspersG.J., VeermanA.J., PietersR., et al.. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood, 1997, 90(7): 2723-2729

[4] YamadaS., HongoT., OkadaS., et al.. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia, 2001, 15(12): 1892-1897

[5] OkadaS., HongoT., YamadaS., et al.. In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia. Br J Haematol, 2003, 123(5): 802-809

[6] DubbersA., WurthweinG., MullerH.J., et al.. Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br J Haematol, 2000, 109(2): 427-429

[7] MullerH.J., BoosJ.. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol, 1998, 28(2): 97-113

[8] MillerH.K., SalserJ.S., BalisM.E.. Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy. Cancer Res, 1969, 29(1): 183-187

[9] OhnumaT., HollandJ.F., FreemanA., et al.. Biochemical and pharmacological studies wih asparaginase in man. Cancer Res, 1970, 30(9): 2297-2305

[10] RichardsN.G., SchusterS.M.. Mechanistic issues in asparagine synthetase catalysis. Adv Enzymol Relat Areas Mol Biol, 1998, 72N: 145-198

[11] LiB.S., GuL.J., LuoC.Y., et al.. The downregulation of asparagine synthetase expression can increase the sensitivity of cells resistant to L-asparaginase. Leukemia, 2006, 20(12): 2199-2201

[12] AppelI.M., den BoerM.L., MeijerinkJ.P., et al.. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood, 2006, 107(11): 4244-4249

[13] HollemanA., den BoerM.L., KazemierK.M., et al.. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood, 2003, 102(13): 4541-4546

[14] LeslieM., CaseM.C., HallA.G., et al.. Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia. Br J Haematol, 2006, 132(6): 740-742

[15] AndoM., SugimotoK., KitohT., et al.. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol, 2005, 130(6): 860-868

[16] AslanianA.M., KilbergM.S.. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J, 2001, 358(Pt1): 59-67

[17] HaskellC.M., CanellosG.P.. L-asparaginase resistance in human leukemia—asparagine synthetase. Biochem Pharmacol, 1969, 18(10): 2578-2580

[18] KiriyamaY., KubotaM., TakimotoT., et al.. Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia, 1989, 3(4): 294-297

[19] CodegoniA.M., BiondiA., ConterV., et al.. Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase. Leukemia, 1995, 9(2): 360-361

[20] Barbosa-TessmannI.P., ChenC., ZhongC., et al.. Activation of the human asparagine synthetase gene by the amino acid response and the endoplasmic reticulum stress response pathways occurs by common genomic elements. J Biol Chem, 2000, 275(35): 26976-26985

[21] JousseC., AverousJ., BruhatA., et al.. Amino acids as regulators of gene expression: molecular mechanisms. Biochem Biophys Res Commun, 2004, 313(2): 447-452

[22] FafournouxP., BruhatA., JousseC.. Amino acid regulation of gene expression. Biochem J, 2000, 351(Pt1N): 1-12

[23] HutsonR.G., KitohT., Moraga AmadorD.A., et al.. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol, 1997, 272(5Pt1): C1691-C1699

[24] GuerriniL., GongS.S., MangasarianK., et al.. Cis- and trans-acting elements involved in amino acid regulation of asparagine synthetase gene expression. Mol Cell Biol, 1993, 13(6): 3202-3212

[25] GrecoA., GongS.S., IttmannM., et al.. Organization and expression of the cell cycle gene, ts11, that encodes asparagine synthetase. Mol Cell Biol, 1989, 9(6): 2350-2359

[26] HongoS., SakagamiH., SatoT.. Decrease in asparagine synthetase activity during cell differentiation of mouse and human leukemia cell lines. Leukemia, 1990, 4(10): 708-711

[27] RichardsN.G., KilbergM.S.. Asparagine synthetase chemotherapy. Annu Rev Biochem, 2006, 75N: 629-654

[28] FineB.M., KaspersG.J., HoM., et al.. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res., 2005, 65(1): 291-299

[29] PalacinM., EstevezR., BertranJ., et al.. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev, 1998, 78(4): 969-1054

[30] IwamotoS., MiharaK., DowningJ.R., et al.. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest, 2007, 117(4): 1049-1057

[31] RubartelliA., SitiaR.. Interleukin 1 beta and thioredoxin are secreted through a novel pathway of secretion. Biochem Soc Trans, 1991, 19(2): 255-259

[32] RubartelliA., BajettoA., AllavenaG., et al.. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem, 1992, 267(34): 24161-24164

[33] MignattiP., MorimotoT., RifkinD.B.. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol, 1992, 151(1): 81-93

[34] MehulB., HughesR.C.. Plasma membrane targetting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. J Cell Sci, 1997, 110(Pt10): 1169-1178

[35] ChangH.C., SamaniegoF., NairB.C., et al.. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS, 1997, 11(12): 1421-1431

[36] TanudjiM., HeviS., ChuckS.L.. Improperly folded green fluorescent protein is secreted via a non-classical pathway. J Cell Sci, 2002, 115(Pt19): 3849-3857